AstraZeneca buys US vaccine company in $1.1bn deal

Britain's biggest drugmaker acquires Seattle-based firm Icosavax, expanding vaccine and immune therapy business

AstraZeneca is buying its first vaccine company in a $1.1bn deal that will expand the vaccine and immune therapy business it set up during the Covid pandemic.

Britain's biggest drugmaker has agreed to take over the Seattle-based company Icosavax, which is developing a potential vaccine for two common respiratory diseases.